Volume 24 Issue 2
Feb.  2026
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2026  >  24(2): 221-224
YANG Yongqing, WANG Liping. Efficacy of Tripterygium Wilfordii Polyglycoside Tablets combined Hydroxychloroquine Sulfate and Golimumab in the treatment of elderly-onset rheumatoid arthritis[J]. Chinese Journal of General Practice, 2026, 24(2): 221-224. doi: 10.16766/j.cnki.issn.1674-4152.004365
Citation: YANG Yongqing, WANG Liping. Efficacy of Tripterygium Wilfordii Polyglycoside Tablets combined Hydroxychloroquine Sulfate and Golimumab in the treatment of elderly-onset rheumatoid arthritis[J]. Chinese Journal of General Practice, 2026, 24(2): 221-224. doi: 10.16766/j.cnki.issn.1674-4152.004365
shu

Efficacy of Tripterygium Wilfordii Polyglycoside Tablets combined Hydroxychloroquine Sulfate and Golimumab in the treatment of elderly-onset rheumatoid arthritis

doi: 10.16766/j.cnki.issn.1674-4152.004365
  • 1.

    The Second Clinical College of Lanzhou University, Lanzhou, Gansu 730030, China

Funds:

 18JR3RA319

 CYXZ2023-51

  • Received Date: 2025-01-13
    Available Online: 2026-04-11
    Abstract
  •   Objective  To evaluate the efficacy and safety of Tripterygium Wilfordii Polyglycoside Tablets combined Hydroxychloroquine Sulfate and Golimumab therapy in patients with elderly-onset rheumatoid arthritis (EORA).  Methods  A total of 77 patients diagnosed with EORA at Lanzhou University Second Hospital from June 2018 to December 2022 were enrolled. They were randomly divided into the observation group (40 cases) and the control group (37 cases). Patients were treated for 24 weeks with either Tripterygium glycosides tablets and Hydroxychloroquine Sulfate or Iguratimod combined with golimumab. The primary efficacy endpoints were the American College of Rheumatology 20% (ACR20), 50% (ACR50), and 70% (ACR70) response rates. The secondary efficacy endpoint was the 28-joint Disease Activity Score (DAS28) remission rate. Adverse effects were assessed throughout the treatment period.  Results  At week 24, the proportions of ACR20, ACR50, ACR70, and DAS28 in the observation group was 97.44% (38/39), 84.62% (33/39), 69.23% (27/39), and 87.18% (34/39), respectively. In the control group, the proportion of ACR20, ACR50, ACR70, and DAS28 was 97.06% (33/34), 88.24% (30/34), 70.59% (24/34), and 76.47% (26/34), respectively. One patient in the observation group was lost to follow-up. In the control group, one patient was lost to follow-up and 2 patients withdrew from the treatment.  Conclusion  Tripterygium glycosides tablets or Iguratimod combined with Hydroxychloroquine Sulfate and Golimumab can effectively relieve clinical symptoms in patients with EORA with acceptable safety profiles. The treatment regimen in the observation group was more cost-effective. Therefore, Tripterygium glycosides tablets combined with Hydroxychloroquine Sulfate and Golimumab represents a therapeutic strategy worthy of broader clinical application.

     

    • FullText(HTML)
  • loading
    • References(15)
  • [1]
    谢文慧, 张卓莉. 类风湿关节炎达标治疗: 十年磨一剑[J]. 中华风湿病学杂志, 2020, 24(11): 721-724.

    XIE W H, ZHANG Z L. Targeted treatment of rheumatoid arthritis in the elderly: ten years of grinding the sword[J]. Chinese Journal of Rheumatology, 2020, 24(11): 721-724.
    [2]
    YU M B, FIREK A, LANGRIDGE W H R. Predicting methotrexate resistance in rheumatoid arthritis patients[J]. Inflammopharmacology, 2018, 26(3): 699-708. doi: 10.1007/s10787-018-0459-z
    [3]
    宋梦婷, 王振杰, 郭培霞, 等. 老年起病类风湿关节炎的诊治进展[J]. 中华全科医学, 2021, 19(4): 648-652. doi: 10.16766/j.cnki.issn.1674-4152.001884

    SONG M T, WANG Z J, GUO P X, et al. Advances in the diagnosis and treatment of rheumatoid arthritis in elderly patients[J]. Chinese Journal of General Practice, 2021, 19(4): 648-652. doi: 10.16766/j.cnki.issn.1674-4152.001884
    [4]
    姜楠, 田新平, 曾小峰. 《2024中国类风湿关节炎诊疗指南》解读[J]. 中华内科杂志, 2024, 63(11): 1059-1077.

    JIANG N, TIAN X P, ZENG X F. Interpretation of 2024 Chinese guidelines for the diagnosis and treatment of rheumatoid arthritis[J]. Chinese Journal of Internal Medicine, 2024, 63(11): 1059-1077.
    [5]
    吴歆, 戚务芳, 王志强, 等. 风湿病靶向药物使用规范[J]. 中华内科杂志, 2022, 61(7): 756-763.

    WU X, QI W F, WANG Z Q, et al. Specifications for the use of targeted drugs in rheumatic diseases[J]. Chinese Journal of Internal Medicine, 2022, 61(7): 756-763.
    [6]
    ARNETT F C, EDWORTHY S M, BLOCH D A, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis[J]. Arthritis Rheum, 1988, 31(3): 315-324. doi: 10.1002/art.1780310302
    [7]
    ALETAHA D, NEOGI T, SILMAN A J, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative[J]. Arthritis Rheum, 2010, 62(9): 2569-2581. doi: 10.1002/art.27584
    [8]
    SAAG K G, TENG G G, PATKAR N M, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis[J]. Arthritis Rheum, 2008, 59(6): 762-784. doi: 10.1002/art.23721
    [9]
    田新平, 曾小峰. 戈利木单抗治疗类风湿关节炎的进展[J]. 中华风湿病学杂志, 2019, 23(6): 423-425.

    TIAN X P, ZENG X F. Progress in the treatment of rheumatoid arthritis in the elderly with golimumab[J]. Chinese Journal of Rheumatology, 2019, 23(6): 423-425.
    [10]
    彭昭, 王迁, 康琳. 老年类风湿关节炎的研究进展[J]. 中国临床保健杂志, 2024, 27(4): 443-447.

    PENG Z, WANG Q, KANG L. Research progress of rheumatoid arthritis in the elderly[J]. Chinese Journal of Clinical Healthcare, 2024, 27(4): 443-447.
    [11]
    PELECHAS E, VOULGARI P V, DROSOS A A. Golimumab for rheumatoid arthritis[J]. J Clin Med, 2019, 8(3): 387. DOI: 10.3390/jcm8030387.
    [12]
    MICHAUD K, POPE J, VAN DE LAAR M, et al. Systematic literature review of residual symptoms and an unmet need in patients with rheumatoid arthritis[J]. Arthritis Care Res (Hoboken), 2021, 73(11): 1606-1616. doi: 10.1002/acr.24369
    [13]
    FLETCHER A, LASSERE M, MARCH L, et al. Patterns of biologic and targeted-synthetic disease-modifying antirheumatic drug use in rheumatoid arthritis in Australia[J]. Rheumatology (Oxford), 2022, 61(10): 3939-3951. doi: 10.1093/rheumatology/keac048
    [14]
    REVEILLE J D, DEODHAR A, CALDRON P H, et al. Safety and efficacy of intravenous Golimumab in adults with ankylosing spondylitis: results through 1 year of the GO-ALIVE study[J]. J Rheumatol, 2019, 46(10): 1277-1283. doi: 10.3899/jrheum.180718
    [15]
    DELPECH CÉLIA, LABORNE F X, HILLIQUIN P. Comparison of biological agent monotherapy and associations including disease-modifying antirheumatic drugs for rheumatoid arthritis: literature review and meta-analysis of randomized trials[J]. J Clin Med, 2022, 12(1): 286. DOI: 10.3390/jcm12010286.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (7) PDF downloads(0) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return